Similar articles

• FDA advisory panel voices persistent safety concerns.

  Finkelstein JB. Finkelstein JB. J Natl Cancer Inst. 2006 Apr 5;98(7):439. doi: 10.1093/jnci/djj149. J Natl Cancer Inst. 2006. PMID: 16595778 No abstract available.
• FDA attempting to overcome major roadblocks in monitoring drug safety.

  Zielinski SL. Zielinski SL. J Natl Cancer Inst. 2005 Jun 15;97(12):872-3. doi: 10.1093/jnci/97.12.872. J Natl Cancer Inst. 2005. PMID: 15956645 No abstract available.
• Opening Pandora's pillbox: using modern information tools to improve drug safety.

  Gottlieb S. Gottlieb S. Health Aff (Millwood). 2005 Jul-Aug;24(4):938-48. doi: 10.1377/hlthaff.24.4.938. Health Aff (Millwood). 2005. PMID: 16012136
• Regulatory considerations for determining postmarketing study commitments.

  Meyer RJ. Meyer RJ. Clin Pharmacol Ther. 2007 Aug;82(2):228-30. doi: 10.1038/sj.clpt.6100238. Epub 2007 May 30. Clin Pharmacol Ther. 2007. PMID: 17538552 Review.
• An overview of FDA medical device regulation as it relates to deep brain stimulation devices.

  Peña C, Bowsher K, Costello A, De Luca R, Doll S, Li K, Schroeder M, Stevens T. Peña C, et al. IEEE Trans Neural Syst Rehabil Eng. 2007 Sep;15(3):421-4. doi: 10.1109/TNSRE.2007.903973. IEEE Trans Neural Syst Rehabil Eng. 2007. PMID: 17894274 Review.